Connect with us

Hi, what are you looking for?

Trading Secrets

mRNA’s Progressive Technology in Treating Rare Diseases

mRNA’s Progressive Technology in Treating Rare Diseases

An interdisciplinary team comprising scientists from UCL, King’s College London, and Moderna has recently demonstrated the transformative potential of mRNA technology in treating argininosuccinic aciduria, a rare and inherited metabolic disorder.

Argininosuccinic aciduria, impacting approximately one in 100,000 newborns, disrupts protein breakdown. The latter potentially results in elevated ammonia levels and imbalanced glutathione regulation vital for liver detoxification.

Venturing into Human Trials: The Next Frontier

The research team, fueled by the ambition to push medical boundaries, is gearing up for human trials in the coming years. Simultaneously, Moderna is sponsoring global clinical trials at Great Ormond Street Hospital for Children. Moreover, it’s exploring mRNA therapies for other rare inherited metabolic diseases like propionic and methylmalonic acidaemias.

Innovative Technology in Treating Genetic Diseases

Dr. Julien Baruteau, Co-lead Principal Investigator, emphasized the revolutionary impact of messenger RNA on the field of vaccines during the COVID-19 pandemic. She also asserted the belief that it holds the potential to have similar transformative results on rare diseases. The latter, affecting around 300 million people globally, often results from DNA errors, with less than 5% having approved therapies.

Navigating from Gene Therapy to mRNA Innovation

Traditionally, gene therapy, using modified viruses, was a standard approach for treating genetic diseases. However, these methods posed challenges, including adverse effects. Seeking an alternative, the research team delved into the application of mRNA technology as a progressive solution. Messenger RNA, encapsulated in lipid microdroplets, provided a precise and targeted therapy for liver cells.

Moreover, testing the therapy on mice with argininosuccinic aciduria yielded promising results. The benefit of each mRNA treatment lasted approximately seven days. However, weekly administrations over eight weeks proved effective. The researchers employed positron emission tomography (PET) scans to monitor the correction of glutathione regulation.

A Glimpse into the Future: Propelling Hope for Patients

Dr. Baruteau emphasized the unprecedented therapeutic potential of mRNA, particularly for incurable genetic diseases such as liver conditions. The intention is to extend this approach to various inherited liver diseases, ultimately translating mRNA therapy to patients, especially children.

Synergistic Science in Action

Dr. Tim Witney, Co-lead PI at King’s College London, praised the collaborative effort, emphasizing the real-time correction of genetic errors through imaging. Dr. Paolo Martini, Chief Scientific Officer at Moderna, also underscored the synergy between academia and industry in exploring mRNA technology’s potential against rare diseases.

Funding a Future of Medical Breakthroughs

The research received support from various entities, including Moderna, the Medical Research Council, the London Advanced Therapies consortium, Wellcome, Cancer Research UK, and the National Institute for Health and Care Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre.

Innovative Technology: Catalyst for Change

As the study delves into the possibilities of mRNA therapy, it becomes evident that this innovative technology holds immense promise. Beyond correcting genetic errors, it opens avenues for treating a spectrum of rare genetic diseases.

Besides, with this progressive technology spearheading potential cures, the healthcare sector experiences a surge in demand for professionals adept at harnessing mRNA’s power. These technology jobs mark a new era for medical research and application.

Embracing a New Era in Technology

As mRNA therapy establishes itself as a frontrunner in medical advancements, we witness the dawn of a new era in technology. This creative technology not only addresses genetic disorders but also signals a paradigm shift in how we approach and treat rare diseases.

Moreover, the study unveils the promising potential of mRNA technology, marking a significant stride towards treating rare genetic diseases and instilling hope globally. With progressive technology at the forefront, the medical field stands on the brink of transformative change, ushering in a new era of possibilities.

The post mRNA’s Progressive Technology in Treating Rare Diseases appeared first on FinanceBrokerage.

Enter your email address below and we’ll send you our best practices.

    You can unsubscribe at any time. Redstatefoundation respects your privacy and strives to be transparent about our data collection practices. Please read our Privacy Policy and Terms of Use.

    You May Also Like

    Trading Life

    Laura Wong Hon Chan is an interest rate options trader, who is currently a director at Bank of America Merrill Lynch in New York....

    Trading Secrets

    In this episode of StockCharts TV‘s The MEM Edge, Mary Ellen reviews what’s driving the markets higher and what to be on the lookout...

    Trading Secrets

    SPX Monitoring Purposes: Long SPX on 10/10/22 at 3612.39; sold 12/13/22 at 3669.91 = gain 1.59%. Monitoring Purposes GOLD: Long GDX on 10/9/20 at...

    Trading Secrets

    I don’t like it when parts of a puzzle don’t match. You just don’t get a clear picture. As participants in the markets, we...